BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18171726)

  • 1. Eplerenone after myocardial infarction?
    Drug Ther Bull; 2008 Jan; 46(1):1-3. PubMed ID: 18171726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G; Solesse A; Beillat M
    Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone in the treatment of chronic heart failure.
    Krum H; Liew D
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):315-20. PubMed ID: 15151479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pfizer launches Inspra for heart failure.
    Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001435
    [No Abstract]   [Full Text] [Related]  

  • 7. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone blockade in post-acute myocardial infarction heart failure.
    Pitt B; Ferrari R; Gheorghiade M; van Veldhuisen DJ; Krum H; McMurray J; Lopez-Sendon J
    Clin Cardiol; 2006 Oct; 29(10):434-8. PubMed ID: 17063946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
    Pitt B
    J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
    Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone is not superior to older and less expensive aldosterone antagonists.
    Chatterjee S; Moeller C; Shah N; Bolorunduro O; Lichstein E; Moskovits N; Mukherjee D
    Am J Med; 2012 Aug; 125(8):817-25. PubMed ID: 22840667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?
    Doggrell S
    Expert Opin Pharmacother; 2003 Sep; 4(9):1605-7. PubMed ID: 12943490
    [No Abstract]   [Full Text] [Related]  

  • 16. Eplerenone in patients with left ventricular dysfunction.
    Blaustein DA; Schwenk MH
    N Engl J Med; 2003 Jul; 349(1):88-9; author reply 88-9.. PubMed ID: 12846224
    [No Abstract]   [Full Text] [Related]  

  • 17. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
    Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.